Cargando…

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis

IncobotulinumtoxinA, a pure botulinumtoxinA formulation, is free of accessory proteins. This analysis provides pooled safety data from phase 3 trials of children/adolescents (2–17 years), investigating incobotulinumtoxinA for the treatment of spasticity associated with cerebral palsy (at doses ≤20 U...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berweck, Steffen, Banach, Marta, Gaebler-Spira, Deborah, Chambers, Henry G., Schroeder, A. S., Geister, Thorin L., Althaus, Michael, Hanschmann, Angelika, Vacchelli, Matteo, Bonfert, Michaela V., Heinen, Florian, Dabrowski, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505819/ https://www.ncbi.nlm.nih.gov/pubmed/36136523 http://dx.doi.org/10.3390/toxins14090585

Ejemplares similares

Spasticity-related pain in children/adolescents with cerebral palsy. Part 2: IncobotulinumtoxinA efficacy results from a pooled analysis
por: Bonfert, Michaela, et al.
Publicado: (2023)

IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study(1)
por: Heinen, Florian, et al.
Publicado: (2021)

Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy
por: Kaňovský, Petr, et al.
Publicado: (2022)

Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI
por: Berweck, Steffen, et al.
Publicado: (2021)

Spasticity-related pain in children/adolescents with cerebral palsy. Part 1: Prevalence and clinical characteristics from a pooled analysis
por: Heinen, Florian, et al.
Publicado: (2022)

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults
por: Jost, Wolfgang H., et al.
Publicado: (2023)

SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
por: Jost, Wolfgang H., et al.
Publicado: (2019)

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis
por: Kaňovský, Petr, et al.
Publicado: (2021)

Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Wissel, Jörg, et al.
Publicado: (2021)

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions
por: Makino, Koji, et al.
Publicado: (2020)

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis
por: Albanese, Alberto, et al.
Publicado: (2023)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato, Andrea
Publicado: (2016)

IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study
por: Wu, Yan, et al.
Publicado: (2023)

Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA
por: Fheodoroff, Klemens, et al.
Publicado: (2020)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study
por: Marciniak, Christina, et al.
Publicado: (2018)

Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE)
por: Masakado, Yoshihisa, et al.
Publicado: (2020)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
por: Ianieri, Giancarlo, et al.
Publicado: (2018)

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
por: Wissel, Jörg, et al.
Publicado: (2017)

SUSTAINED EFFICACY OF INCOBOTULINUMTOXINA FOLLOWING REPEATED INJECTIONS FOR UPPER-LIMB POST-STROKE SPASTICITY: A POST HOC ANALYSIS
por: KAŇOVSKÝ, Petr, et al.
Publicado: (2020)

Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity
por: Elovic, Elie Paul, et al.
Publicado: (2015)

IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability
por: León-Valenzuela, Angel, et al.
Publicado: (2020)

IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations
por: Yutskovskaya, Yana, et al.
Publicado: (2015)

Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience
por: Martínez-Poles, Javier, et al.
Publicado: (2018)

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders
por: Jost, Wolfgang H, et al.
Publicado: (2015)

Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
por: Dressler, Dirk, et al.
Publicado: (2013)

Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager, Welf
Publicado: (2013)

Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study
por: Jog, Mandar, et al.
Publicado: (2020)

Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques
por: Nikolis, Andreas, et al.
Publicado: (2018)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

One21: A Novel, Customizable Injection Protocol for Treatment of the Forehead with IncobotulinumtoxinA
por: de Sanctis Pecora, Carla
Publicado: (2020)

IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
por: Hosseini, Meghdad, et al.
Publicado: (2023)

Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study
por: Dressler, Dirk, et al.
Publicado: (2015)

IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study
por: Pavicic, Tatjana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_n33l0c9fij8qef96gifus1g29m